Mediwhale

Paid

AI-powered retinal scanning for non-invasive cardiovascular and systemic disease risk prediction.

Capabilities: Cardiovascular risk assessment Chronic kidney disease prediction Biological age estimation Retinal disease screening Automated clinical reporting

Visit Website

9.5

Protocol Reliability Score

Overview

Mediwhale is a pioneer in the AI-driven health diagnostics space, specifically focusing on the retina as a non-invasive window into systemic health. Their flagship platform, Reti-Intelligence (including Reti-CVD and Reti-CKD), utilizes deep learning algorithms trained on massive longitudinal datasets, such as the UK Biobank, to predict cardiovascular and kidney disease risks with accuracy levels comparable to traditional, invasive tests like Coronary Artery Calcium (CAC) scoring. By 2026, Mediwhale has positioned itself as a critical bridge between ophthalmology and preventive primary care, enabling clinicians to assess systemic risks within seconds using standard fundus cameras. The technical architecture is built on a proprietary convolutional neural network (CNN) stack that analyzes microvascular changes in the retina—indicators often invisible to the human eye. This allows for early intervention in high-risk patients who might otherwise bypass traditional screening due to cost or radiation concerns associated with CT scans. The solution is designed for seamless integration into existing hospital EHR systems and diagnostic workflows via DICOM and HL7 standards, facilitating its role in large-scale population health management and corporate wellness programs.